ZOETIS INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 151.2 USD | +1.09% |
|
-0.45% | -23.37% |
| Apr. 23 | Barclays Adjusts Zoetis' Price Target to $230 From $260, Keeps Overweight Rating | MT |
| Apr. 22 | Jefferies Lowers Zoetis Price Target to $200 from $220 | MT |
Presenter SpeechNathan Rich (Analysts)Good afternoon, everyone, and thank you so much for join...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Zoetis Inc. specializes in developing, manufacturing and marketing of animal health products. Net sales break down by activity as follows:
- pets (64.4%): cats and dogs (94.9% of net sales) and horses (5.1%);
- livestock (34.5%): cattle (51.6% of sales), swine (20.2%), poultry (17.1%), fish (7.6%) and other (3.5%);
- other (1.1%).
Net sales break down by family of products into parasiticides (23%), vaccines (21.3%), dermatological products (16.4%), anti-infectives (13.4%), medical food additives (4.5%), diagnostic products (4.4%) and other (17%).
At the end of 2022, the group has 29 production sites worldwide.
The United States accounts for 53.4% of net sales.
Sector
Pharmaceuticals
Calendar
2024-05-02
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
19
Last Close Price
149.6
USD
Average target price
215.2
USD
Spread / Average Target
+43.87%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -23.37% | 68.34B | |
| -10.67% | 6.64B | |
| +16.00% | 3.41B | |
| +0.14% | 3.21B | |
| +2.53% | 1.46B | |
| -14.67% | 1.38B | |
| -2.44% | 1.25B | |
| -27.57% | 1.21B | |
| -12.86% | 1.13B | |
| -2.99% | 1.03B |
- Stock Market
- Equities
- ZTS Stock
- News Zoetis Inc.
- Transcript : Zoetis Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-13-2022 01
